Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Tetrasomy 8 in a patient with chronic lymphocytic leukemia

Texto completo
Autor(es):
de Oliveira, Fabio Morato [1] ; Brandao, Renata Amorim [1] ; Leite-Cueva, Sabrina Dias [2] ; Careta, Francisco de Paula [1] ; Simoes, Belinda Pinto [1] ; Rego, Eduardo Magalhaes [1] ; Falcao, Roberto Passetto [1]
Número total de Autores: 7
Afiliação do(s) autor(es):
[1] Univ Sao Paulo, Sch Med Ribeirao Preto, Div Hematol, Dept Internal Med, BR-14049900 Ribeirao Preto, SP - Brazil
[2] Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Genet, BR-14049900 Ribeirao Preto, SP - Brazil
Número total de Afiliações: 2
Tipo de documento: Artigo Científico
Fonte: Cancer Genetics and Cytogenetics; v. 198, n. 2, p. 166-169, APR 15 2010.
Citações Web of Science: 1
Resumo

We report a case of a 47-year-old man diagnosed with chronic lymphocytic leukemia (CLL) with two extra copies of chromosome 8. Classical cytogenetic analysis by the immunostimulatory combination of DSP30 and interleukin 2 showed tetrasomy of chromosome 8 in 60% of the metaphase cells (48,XY,+8,+8{[}12]/46,XY{[}8]). Spectral karyotype analysis confirmed the abnormality previously seen by G banding. Additionally, interphase fluorescence in situ hybridization using an LSI CEP 8 probe performed on peripheral blood cells without any stimulant agent showed tetrasomy of chromosome 8 in 54% of analyzed cells (108 of 200). To our knowledge, tetrasomy 8 as the sole chromosomal abnormality in CLL has not been previously described. The prognostic significance of tetrasomy 8 in CLL remains to be elucidated. However, the patient has been followed up in the outpatient hospital since 2004 without any therapeutic intervention and has so far remained stable. (C) 2010 Elsevier Inc. All rights reserved. (AU)

Processo FAPESP: 07/52462-7 - Citogenética clássica e cariótipo espectral (SKY) aplicados à caracterização da leucemia linfocítica crônica B (LLC-B) imunoestimulada pelo oligonucleotídeo DSP30 e IL-2
Beneficiário:Fábio Morato de Oliveira
Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado